{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:14:01Z","timestamp":1788984841253,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01845-4","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:15:47Z","timestamp":1782990947000},"page":"4375-4386","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8808-6781","authenticated-orcid":false,"given":"Luciana A.","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5759-2727","authenticated-orcid":false,"given":"Patr\u00edcia S.","family":"Kurizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1788-7070","authenticated-orcid":false,"given":"Rodrigo R.","family":"de Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4455-2017","authenticated-orcid":false,"given":"Samia","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5015-8000","authenticated-orcid":false,"given":"Gabriel B. F.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4486-1892","authenticated-orcid":false,"given":"Let\u00edcia O.","family":"Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-5121","authenticated-orcid":false,"given":"Licia Maria H.","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-6884","authenticated-orcid":false,"given":"Ciro M.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"1845_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.M1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/BMJ.M1590.","journal-title":"BMJ"},{"key":"1845_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/PTT.S513878","volume":"15","author":"L D\u2019Almeida","year":"2025","unstructured":"D\u2019Almeida L, Duarte G, Godinho MP, Cariello L, Sousa GJ, Gomes C. Analysis of the reduction in the duration of sick leave for 32,512 psoriasis patients following the integration of targeted therapies for psoriatic disease into the Brazilian healthcare system: a retrospective cohort study. Psoriasis. 2025;15:105\u201316. https:\/\/doi.org\/10.2147\/PTT.S513878.","journal-title":"Psoriasis"},{"key":"1845_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/J.LANA.2025.101295","volume":"51","author":"A Padilha","year":"2025","unstructured":"Padilha A, Massuda A, Le\u00f4nidas F, Davidian A. Thirty-five years of Brazil\u2019s Unified Health System (SUS): from Alma-ata to the climate challenge. The Lancet Reg Health - Am. 2025;51:101295. https:\/\/doi.org\/10.1016\/J.LANA.2025.101295.","journal-title":"The Lancet Reg Health - Am"},{"issue":"3","key":"1845_CR4","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1111\/jdv.20196","volume":"39","author":"LFV d\u2019 Almeida","year":"2025","unstructured":"d\u2019Almeida LFV, Borghi de Oliveira AC, Carvalho Neiva B, et\u00a0al. Financial impact on social security of the incorporation of adalimumab for the treatment of hidradenitis suppurativa: an analysis of the 61-million-contributor Brazilian Social Security System (INSS). J Eur Acad Dermatol Venereol. 2025;39(3):e206\u20138. https:\/\/doi.org\/10.1111\/jdv.20196.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1845_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.abd.2020.08.011","volume":"96","author":"EC de Lima","year":"2021","unstructured":"de Lima EC, Boza JC, Palominos PE, Xavier RM, Cestari TF. Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil. An Bras Dermatol. 2021;96:376\u20139. https:\/\/doi.org\/10.1016\/j.abd.2020.08.011.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1845_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.ABD.2023.03.002","volume":"99","author":"NRdeM Alves","year":"2023","unstructured":"Alves NRdeM, Kurizky PS, da Mota LMH, et\u00a0al. Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study. An Bras Dermatol. 2023;99(1):34\u201342. https:\/\/doi.org\/10.1016\/J.ABD.2023.03.002.","journal-title":"An Bras Dermatol"},{"issue":"suppl 2","key":"1845_CR7","doi-asserted-by":"publisher","first-page":"19s","DOI":"10.11606\/S1518-8787.2017051007136","volume":"51","author":"RCRM do Nascimento","year":"2017","unstructured":"do Nascimento RCRM, \u00c1lvares J, Guerra Junior AA, et\u00a0al. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System. Rev Saude Publica. 2017;51(suppl 2):19s. https:\/\/doi.org\/10.11606\/S1518-8787.2017051007136.","journal-title":"Rev Saude Publica"},{"key":"1845_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/BIOSTATISTICS\/KXAC009","volume":"24","author":"MJ Crowther","year":"2022","unstructured":"Crowther MJ, Royston P, Clements M. A flexible parametric accelerated failure time model and the extension to time-dependent acceleration factors. Biostatistics. 2022;24:811. https:\/\/doi.org\/10.1093\/BIOSTATISTICS\/KXAC009.","journal-title":"Biostatistics"},{"issue":"7","key":"1845_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/jpm14070716","volume":"14","author":"E Bellis","year":"2024","unstructured":"Bellis E, Ruscitti P, Donzella D, et\u00a0al. Retention rate of ixekizumab in psoriatic arthritis: a real-world study. J Pers Med. 2024;14(7):716. https:\/\/doi.org\/10.3390\/jpm14070716.","journal-title":"J Pers Med"},{"key":"1845_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","volume":"166","author":"K Reich","year":"2012","unstructured":"Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166:179\u201388. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10583.x.","journal-title":"Br J Dermatol"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/AJD.14254","volume":"65","author":"S Ting","year":"2024","unstructured":"Ting S, Lowe P, Smith A, Fern\u00e1ndez-Pe\u00f1as P. Drug survival of biologics in psoriasis: an Australian multicentre retrospective study. Australas J Dermatol. 2024;65:350\u20137. https:\/\/doi.org\/10.1111\/AJD.14254.","journal-title":"Australas J Dermatol"},{"key":"1845_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/S40257-022-00722-Y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, et\u00a0al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23:891\u2013904. https:\/\/doi.org\/10.1007\/S40257-022-00722-Y.","journal-title":"Am J Clin Dermatol"},{"key":"1845_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3","volume":"1","author":"E Sbidian","year":"2020","unstructured":"Sbidian E, Chaimani A, Afach S, et\u00a0al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"1845_CR14","unstructured":"Brunner M, Holyoak K, DiRuggiero D. Healthcare provider administration of biologics for patients with plaque psoriasis: literature review and clinical considerations. J Clin Aesthet Dermatol. 2023; 16:S20. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10919952\/."},{"issue":"5","key":"1845_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/J.ABD.2025.501165","volume":"100","author":"PBE Canabrava","year":"2025","unstructured":"Canabrava PBE, Beauge RS, Azouz SdeF, et\u00a0al. Evaluation of Tyrosine Kinase-2 (TYK2) signaling pathway gene expression and the presence of the single-nucleotide polymorphism rs12720356 in the peripheral blood of patients with severe psoriasis and loss of systemic treatment response. An Bras Dermatol. 2025;100(5):501165. https:\/\/doi.org\/10.1016\/J.ABD.2025.501165.","journal-title":"An Bras Dermatol"},{"issue":"15","key":"1845_CR16","doi-asserted-by":"publisher","first-page":"12310","DOI":"10.3390\/IJMS241512310","volume":"24","author":"HA Patel","year":"2023","unstructured":"Patel HA, Revankar RR, Pedroza ST, Graham S, Feldman SR. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. Int J Mol Sci. 2023;24(15):12310. https:\/\/doi.org\/10.3390\/IJMS241512310.","journal-title":"Int J Mol Sci"},{"key":"1845_CR17","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V106.ADV-2025-0167","volume":"106","author":"A Duvetorp","year":"2026","unstructured":"Duvetorp A, Reek J, Wikstr\u00f6m J, et\u00a0al. Psoriasis triggers and disease activity: analysis of survey data from the PSODEEP1 study. Acta Derm Venereol. 2026;106:0167. https:\/\/doi.org\/10.2340\/ACTADV.V106.ADV-2025-0167.","journal-title":"Acta Derm Venereol"},{"key":"1845_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/BJD.12654","volume":"170","author":"L Hsu","year":"2014","unstructured":"Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261\u201373. https:\/\/doi.org\/10.1111\/BJD.12654.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1845_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/SRT.13902","volume":"30","author":"AMG Brunasso","year":"2024","unstructured":"Brunasso AMG, Salvi I, Sorbara S, et\u00a0al. Improvement of self-administration experience with a new injection device: real-life experience with risankizumab in patients with psoriasis. Skin Res Technol. 2024;30(8):e13902. https:\/\/doi.org\/10.1111\/SRT.13902.","journal-title":"Skin Res Technol"},{"key":"1845_CR20","doi-asserted-by":"publisher","first-page":"e244246","DOI":"10.1001\/JAMANETWORKOPEN.2024.4246","volume":"7","author":"K Callaway Kim","year":"2024","unstructured":"Callaway Kim K, Rothenberger SD, Tadrous M, et\u00a0al. Drug shortages prior to and during the COVID-19 pandemic. JAMA Netw Open. 2024;7:e244246\u2013e244246. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.4246.","journal-title":"JAMA Netw Open"},{"key":"1845_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/CED\/LLAF349","volume":"51","author":"MT Svendsen","year":"2025","unstructured":"Svendsen MT, M\u00f6ller S, Feldman SR, Andersen KE. Increasing the quantity of topical corticosteroids applied reduces the severity of psoriasis: results from two randomized controlled trials. Clin Exp Dermatol. 2025;51:92\u20137. https:\/\/doi.org\/10.1093\/CED\/LLAF349.","journal-title":"Clin Exp Dermatol"},{"key":"1845_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016336","volume":"2026","author":"L Le Cleach","year":"2026","unstructured":"Le Cleach L, Afach S, Veroniki AA, et\u00a0al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2026;2026:CD016336. https:\/\/doi.org\/10.1002\/14651858.CD016336.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1845_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/S13555-025-01588-8","volume":"16","author":"M Luz","year":"2025","unstructured":"Luz M, Lu\u00edsa Jo\u00e3o A, Mendes-Bastos P, et\u00a0al. Real-world evidence on dose spacing of risankizumab for psoriasis: a multicenter retrospective cohort study. Dermatol Ther. 2025;16(1):653\u201365. https:\/\/doi.org\/10.1007\/S13555-025-01588-8.","journal-title":"Dermatol Ther"},{"key":"1845_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/JAMADERMATOL.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, et\u00a0al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160:953\u201363. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2024.2463.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1845_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/EXD.70122","volume":"34","author":"C Wang","year":"2025","unstructured":"Wang C, Liu Y, Yang Y, et\u00a0al. Extension of secukinumab and ixekizumab dose for moderate-to-severe psoriasis in low disease activity intervals. Exp Dermatol. 2025;34(5):e70122. https:\/\/doi.org\/10.1111\/EXD.70122.","journal-title":"Exp Dermatol"},{"key":"1845_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1001\/JAMADERMATOL.2024.2462","volume":"160","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Conrad C, Noe MH. Extending maintenance dosing intervals for guselkumab in the treatment of patients with psoriasis. JAMA Dermatol. 2024;160:919\u201320. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2024.2462.","journal-title":"JAMA Dermatol"},{"key":"1845_CR27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(25)01675-7","volume":"406","author":"L Puig","year":"2025","unstructured":"Puig L. Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy. Lancet. 2025;406:1316\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(25)01675-7.","journal-title":"Lancet"},{"key":"1845_CR28","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMOA2504187","volume":"393","author":"R Bissonnette","year":"2025","unstructured":"Bissonnette R, Soung J, Hebert AA, et\u00a0al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393:1784\u201395. https:\/\/doi.org\/10.1056\/NEJMOA2504187.","journal-title":"N Engl J Med"},{"key":"1845_CR29","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/J.JACI.2021.11.001","volume":"149","author":"IM Catlett","year":"2022","unstructured":"Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022;149:2010-2020.e8. https:\/\/doi.org\/10.1016\/J.JACI.2021.11.001.","journal-title":"J Allergy Clin Immunol"},{"key":"1845_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.JAAD.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et\u00a0al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88:40\u201351. https:\/\/doi.org\/10.1016\/J.JAAD.2022.08.061.","journal-title":"J Am Acad Dermatol"},{"key":"1845_CR31","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/JAMADERMATOL.2024.2701","volume":"160","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Gooderham M, Lynde C, et\u00a0al. Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160:1066\u201374. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2024.2701.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1845_CR32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41467-025-67475-0","volume":"17","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Jiang R, Shi L, et\u00a0al. A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab. Nat Commun. 2025;17(1):733. https:\/\/doi.org\/10.1038\/s41467-025-67475-0.","journal-title":"Nat Commun"},{"key":"1845_CR33","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/S13555-026-01707-Z","volume":"16","author":"T Torres","year":"2026","unstructured":"Torres T, Blauvelt A, Torres T, Blauvelt A. High-dose, extended half-life IL-23 inhibitors: the next big step in psoriasis care? Dermatol Ther. 2026;16:1841\u20135. https:\/\/doi.org\/10.1007\/S13555-026-01707-Z.","journal-title":"Dermatol Ther"},{"key":"1845_CR34","doi-asserted-by":"publisher","unstructured":"Sbidian E, Chaimani A, Guelimi R, et\u00a0al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis. Cochrane Database of Systematic Reviews. 2023; 1\u2013813. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/https:\/\/doi.org\/10.1002\/14651858.CD011535.pub6\/full.","DOI":"10.1002\/14651858.CD011535.pub6\/full"},{"issue":"24","key":"1845_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.193563","volume":"10","author":"D Strawn","year":"2025","unstructured":"Strawn D, Krueger JG, Bissonnette R, et\u00a0al. Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis. JCI Insight. 2025;10(24):e193563. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.193563.","journal-title":"JCI Insight"},{"issue":"6","key":"1845_CR36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/IJD.70380","volume":"65","author":"A Altayf","year":"2026","unstructured":"Altayf A, Lateiresh M, Marwan L, Alfeetouri MY, Zouaoui Y, Elhadi M. Efficacy and safety of oral icotrokinra in moderate-to-severe plaque psoriasis: a systematic review, meta-analysis, and trial sequential analysis. Int J Dermatol. 2026;65(6):1144\u201354. https:\/\/doi.org\/10.1111\/IJD.70380.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1845_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/S40257-026-01019-0","volume":"27","author":"C Ferreira","year":"2026","unstructured":"Ferreira C, Torres T. Icotrokinra: an oral interleukin-23 receptor antagonist peptide for the treatment of psoriasis. Am J Clin Dermatol. 2026;27(3):479\u201392. https:\/\/doi.org\/10.1007\/S40257-026-01019-0.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1845_CR38","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.18553\/JMCP.2020.26.10.1246","volume":"26","author":"R Bhattacharya","year":"2020","unstructured":"Bhattacharya R, Herren K, Poonawalla I, Bunniran S, Bloomfield A, Schwab P. Comparing medical utilization and cost outcomes in oral versus injectable immunotherapy users with chronic inflammatory joint and skin diseases. J Manag Care Spec Pharm. 2020;26(10):1246\u201356. https:\/\/doi.org\/10.18553\/JMCP.2020.26.10.1246.","journal-title":"J Manag Care Spec Pharm"},{"key":"1845_CR39","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/S13555-023-01034-7","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Warren RB, Zhong Y, et\u00a0al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis. Dermatol Ther. 2023;13:2839\u201357. https:\/\/doi.org\/10.1007\/S13555-023-01034-7.","journal-title":"Dermatol Ther"},{"key":"1845_CR40","doi-asserted-by":"publisher","first-page":"A568","DOI":"10.1016\/j.jval.2013.08.1521","volume":"16","author":"N Barclay","year":"2013","unstructured":"Barclay N, Tarallo M, Hendrikx T, Marett S. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. Value Health. 2013;16:A568. https:\/\/doi.org\/10.1016\/j.jval.2013.08.1521.","journal-title":"Value Health"},{"key":"1845_CR41","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/PPA.S463354","volume":"18","author":"JT Myers","year":"2024","unstructured":"Myers JT, Van Dam J, Imran M, Hashim M, Dhalla AK. Preference for a novel oral alternative to parenterally administered medications. Patient Prefer Adher. 2024;18:1547\u201362. https:\/\/doi.org\/10.2147\/PPA.S463354.","journal-title":"Patient Prefer Adher"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01845-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:33Z","timestamp":1788981693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01845-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Luciana Alves Ribeiro does not have conflicts of interest to disclose. Dr. Patr\u00edcia Shu Kurizky is a consultant, lecturer, and\/or researcher for Boehringer-Ingelheim, Johnson & Johnson, UCB, and Novartis. Mr. Rodrigo Ramos de Sena is a consultant for the Brazilian Ministry of Health. Samia Fares and Gabriel B F dos Santos are employees of Bristol Myers Squibb. Dr. Let\u00edcia Oba Galv\u00e3o is a consultant, lecturer, and\/or researcher for Johnson & Johnson, UCB, Novartis, and AbbVie. Professor Licia Maria Henruique da Mota has received personal or institutional support from AbbVie, Janssen, Pfizer, and Roche; has delivered speeches at events related to this work; and is sponsored by AbbVie, Boehringer-Ingelheim, GSK, Janssen, Libbs, Lilly, Novartis, Pfizer, Roche, Sandoz, and UCB. Prof. Ciro Martins Gomes is a consultant, lecturer, and\/or researcher for Boehringer-Ingelheim, Johnson & Johnson, UCB, Eli Lilly and Company, Bristol Myers Squibb, Novartis, and AbbVie.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were obtained from a longitudinal registry entitled \u201cAutoimmune Diseases in Real Life in Brazil: A Multicenter Cohort Study Based on the Evaluation of Clinical and Molecular Epidemiology\"; registry no.\/approval no. CAAE: 68,068,323.3.1001.5558. The registry received approval from the Research Ethics Committee of the Faculty of Medicine of the University of Bras\u00edlia, Brazil. All patients signed informed consent forms.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}